当前位置:
X-MOL 学术
›
Biochem. Pharmacol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor [1-[2′,5′-Bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3-N-methyl-thymine]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-
BIOCHEMICAL PHARMACOLOGY ( IF 5.3 ) Pub Date : 1993-07-01 , DOI: 10.1016/0006-2952(93)90349-2 Jan Balzarini , Lieve Naesens , Christina Bohman , Maria-Jésus Pérez-Pérez , Ana San-Félix , Maria-Jose Camarasa , Erik de Clercq
BIOCHEMICAL PHARMACOLOGY ( IF 5.3 ) Pub Date : 1993-07-01 , DOI: 10.1016/0006-2952(93)90349-2 Jan Balzarini , Lieve Naesens , Christina Bohman , Maria-Jésus Pérez-Pérez , Ana San-Félix , Maria-Jose Camarasa , Erik de Clercq
[1-[2′,5′-Bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3-N-methyl-thymine]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″ (TSAO-m3T) is a potent, selective and specific inhibitor of human immunodeficiency virus type 1 replication in vitro. Uptake of TSAO-m3T by human CEM cells is drug concentration-dependent and increased proportionally with increasing initial extracellular TSAO-m3T concentrations up to 20 μg/mL. Within 6 hr of incubation, the cells were almost completely saturated with the test compound; further incubation up to 72 hr did not markedly increase the intracellular concentration of the compound. No intracellular metabolic conversion of TSAO-m3T was observed in CEM, MT-4 or MOLT-4 cells. Upon intravenous bolus administration of TSAO-m3T to mice at 0.75 mg/kg, TSAO-m3T was rapidly cleared from the plasma in a mono-exponential manner (half-life: 22 min; distribution volume: 9.5 L/kg; total body clearance: 17.8 L/hr/kg). TSAO-m3T mainly accumulated in the lungs, followed by the heart, kidney and liver. Significant amounts of different metabolites of TSAO-m3T were detected in most tissues, the liver, kidney and spleen being the organs that showed the most extensive metabolism. The principal metabolites identified were TSAO-m3T derivatives in which the t-butyldimethylsilyl moiety at C-2′ and/or C-5′ had been split off. The free base N3-methylthymine was not detected.
中文翻译:
抗HIV-1特异性抑制剂[1- [2',5'-Bis-O-(叔丁基二甲基甲硅烷基)-β-d-呋喃呋喃糖基] -3-N-甲基胸腺嘧啶] -3的代谢和药代动力学′-spiro-5″-(4″-氨基-1″,2″-草硫醇-
TSAO-m3T以单指数方式从血浆中快速清除(半衰期:22分钟;分配体积:9.5 L / kg;总体清除率:17.8 L / hr / kg)。TSAO-m3T主要积累在肺中,其次是心脏,肾脏和肝脏。在大多数组织中检测到大量不同的TSAO-m3T代谢产物,肝脏,肾脏和脾脏是表现出最广泛代谢的器官。确定的主要代谢产物是TSAO-m3T衍生物,其中C-2'和/或C-5'处的叔丁基二甲基甲硅烷基部分已被分离出来。未检测到游离碱N3-甲基胸腺嘧啶。在大多数组织中检测到大量不同的TSAO-m3T代谢产物,肝脏,肾脏和脾脏是表现出最广泛代谢的器官。确定的主要代谢产物是TSAO-m3T衍生物,其中C-2'和/或C-5'处的叔丁基二甲基甲硅烷基部分已被分离出来。未检测到游离碱N3-甲基胸腺嘧啶。在大多数组织中检测到大量不同的TSAO-m3T代谢产物,肝脏,肾脏和脾脏是表现出最广泛代谢的器官。确定的主要代谢产物是TSAO-m3T衍生物,其中C-2'和/或C-5'处的叔丁基二甲基甲硅烷基部分已被分离出来。未检测到游离碱N3-甲基胸腺嘧啶。
更新日期:1993-07-01
中文翻译:
抗HIV-1特异性抑制剂[1- [2',5'-Bis-O-(叔丁基二甲基甲硅烷基)-β-d-呋喃呋喃糖基] -3-N-甲基胸腺嘧啶] -3的代谢和药代动力学′-spiro-5″-(4″-氨基-1″,2″-草硫醇-
TSAO-m3T以单指数方式从血浆中快速清除(半衰期:22分钟;分配体积:9.5 L / kg;总体清除率:17.8 L / hr / kg)。TSAO-m3T主要积累在肺中,其次是心脏,肾脏和肝脏。在大多数组织中检测到大量不同的TSAO-m3T代谢产物,肝脏,肾脏和脾脏是表现出最广泛代谢的器官。确定的主要代谢产物是TSAO-m3T衍生物,其中C-2'和/或C-5'处的叔丁基二甲基甲硅烷基部分已被分离出来。未检测到游离碱N3-甲基胸腺嘧啶。在大多数组织中检测到大量不同的TSAO-m3T代谢产物,肝脏,肾脏和脾脏是表现出最广泛代谢的器官。确定的主要代谢产物是TSAO-m3T衍生物,其中C-2'和/或C-5'处的叔丁基二甲基甲硅烷基部分已被分离出来。未检测到游离碱N3-甲基胸腺嘧啶。在大多数组织中检测到大量不同的TSAO-m3T代谢产物,肝脏,肾脏和脾脏是表现出最广泛代谢的器官。确定的主要代谢产物是TSAO-m3T衍生物,其中C-2'和/或C-5'处的叔丁基二甲基甲硅烷基部分已被分离出来。未检测到游离碱N3-甲基胸腺嘧啶。